Literature DB >> 11710723

Chlamydia and Borrelia DNA in synovial fluid of patients with early undifferentiated oligoarthritis: results of a prospective study.

S Schnarr1, N Putschky, M C Jendro, H Zeidler, M Hammer, J G Kuipers, J Wollenhaupt.   

Abstract

OBJECTIVE: More than 50% of patients with synovitis involving 1-4 joints remain classified as having undifferentiated oligoarthritis (UOA) after 1 year of disease. The clinical presentation is often similar to that of reactive arthritis (ReA) and other spondylarthropathies or to Lyme arthritis. We therefore determined how often Chlamydia trachomatis (Ct) and Borrelia burgdorferi (Bb) can be identified in patients with UOA, by using an extensive laboratory approach.
METHODS: We prospectively studied 52 patients with UOA who presented at an early synovitis clinic in a region highly endemic for Lyme disease. Patients were examined by standardized clinical and immunoserologic procedures. Synovial fluid was screened for the presence of Ct and Bb DNA by polymerase chain reaction (PCR). Urine was tested for Ct DNA by ligase chain reaction, and serum was tested for Ct antibodies by enzyme-linked immunosorbent assay and Bb antibodies by hemagglutination test and Western blotting. PCR results in the UOA patients were compared with the results in cohorts of patients with definite rheumatoid arthritis (RA), Lyme arthritis, and Chlamydia-induced arthritis (CIA).
RESULTS: In the synovial fluid of 9 of 52 patients with UOA (17%), we found Ct DNA, and in 6 of the 52 patients (12%), Bb DNA was found. The frequency of bacteria-specific DNA was 50% (7 of 14) in CIA patients and 69% (11 of 16) in patients with Lyme arthritis. No Bb or Ct DNA was found in the synovial fluid of the 31 RA patients.
CONCLUSION: With optimized PCR protocols, it is possible to detect considerable levels of Bb and Ct DNA in the synovial fluid of patients with UOA. Although the presence of bacterial DNA does not unequivocally prove its etiologic significance, we suggest that at least one-third of patients with UOA may have a form of ReA that involves asymptomatic primary infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11710723     DOI: 10.1002/1529-0131(200111)44:11<2679::aid-art447>3.0.co;2-c

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  14 in total

Review 1.  Antibiotic treatment of Lyme borreliosis: what is the evidence?

Authors:  R Dinser; M C Jendro; S Schnarr; H Zeidler
Journal:  Ann Rheum Dis       Date:  2005-04       Impact factor: 19.103

2.  [Evidence-based recommendations for the management of undifferentiated peripheral inflammatory arthritis (UPIA). The German perspective on the international 3e initiative].

Authors:  I H Tarner; K Albrecht; M Fleck; E Gromnica-Ihle; G Keyßer; L Köhler; I Kötter; K Krüger; J Kuipers; H Nüßlein; A Rubbert-Roth; J Wollenhaupt; M Schneider; B Manger; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2014-05       Impact factor: 1.372

3.  [Infection-induced reactive arthritis : etiopathogenesis, clinical spectrum, therapy].

Authors:  M Brzank; J Wollenhaupt
Journal:  Z Rheumatol       Date:  2013-12       Impact factor: 1.372

4.  Importance of sample preparation for molecular diagnosis of lyme borreliosis from urine.

Authors:  A R Bergmann; B L Schmidt; A-M Derler; E Aberer
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

5.  Optimized testing for C. trachomatis DNA in synovial fluid samples in clinical practice.

Authors:  J Freise; I Bernau; S Meier; H Zeidler; J G Kuipers
Journal:  Z Rheumatol       Date:  2015-11       Impact factor: 1.372

6.  Cytokine profile in serum and synovial fluid of arthritis patients with Chlamydia trachomatis infection.

Authors:  Michael C Jendro; Elke Raum; Sebastian Schnarr; Lars Köhler; Henning Zeidler; Jens G Kuipers; Michael Martin
Journal:  Rheumatol Int       Date:  2003-10-31       Impact factor: 2.631

Review 7.  [Applications of molecular pathology in the diagnosis of joint infections].

Authors:  J Kriegsmann; T Hopf; D Jacobs; N Arens; V Krenn; R Schmitt-Wiedhoff; M Kriegsmann; C Heisel; C Biehl; H Thabe; R P H Schmitz; M Lehmann; M Otto
Journal:  Orthopade       Date:  2009-06       Impact factor: 1.087

8.  Reactive and undifferentiated arthritis in North Africa: use of PCR for detection of Chlamydia trachomatis.

Authors:  J G Kuipers; J Sibilia; S Bas; H Gaston; K Granfors; T L Vischer; N Hajjaj-Hassouni; A Ladjouze-Rezig; S Sellami; J Wollenhaupt; H Zeidler; H R Schumacher; M Dougados
Journal:  Clin Rheumatol       Date:  2008-08-08       Impact factor: 2.980

9.  Chlamydia trachomatis-infected macrophages induce apoptosis of activated T cells by secretion of tumor necrosis factor-alpha in vitro.

Authors:  Michael C Jendro; Frederik Fingerle; Tobias Deutsch; Andrea Liese; Lars Köhler; Jens G Kuipers; Elke Raum; Michael Martin; Henning Zeidler
Journal:  Med Microbiol Immunol       Date:  2003-05-15       Impact factor: 3.402

10.  Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study.

Authors:  T K Kvien; J S H Gaston; T Bardin; I Butrimiene; B A C Dijkmans; M Leirisalo-Repo; P Solakov; M Altwegg; P Mowinckel; P-A Plan; T Vischer
Journal:  Ann Rheum Dis       Date:  2004-09       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.